SeaStar Medical Holding Corporation (ICU)
NASDAQ: ICU · Real-Time Price · USD
2.150
+0.030 (1.42%)
At close: Nov 20, 2024, 4:00 PM
2.190
+0.040 (1.86%)
After-hours: Nov 20, 2024, 7:53 PM EST
Company Description
SeaStar Medical Holding Corporation, a medical device company, develops a platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States.
The company offers inflammatory response to fend off infections and repair damaged tissue in the body.
It is also developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure; myocardial stunning in end stage renal disease; and hepatorenal syndrome.
The company is headquartered in Denver, Colorado.
SeaStar Medical Holding Corporation
| Country | United States |
| Founded | 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 12 |
| CEO | Eric Schlorff |
Contact Details
Address: 3513 Brighton Boulevard, Suite 410 Denver, Colorado 80216 United States | |
| Phone | 844 427 8100 |
| Website | seastarmedical.com |
Stock Details
| Ticker Symbol | ICU |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001831868 |
| CUSIP Number | 81256L104 |
| ISIN Number | US81256L1044 |
| Employer ID | 85-3681132 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Eric Schlorff | Chief Executive Officer, President and Executive Director |
| Colonel Kevin Chung FACP, M.D. | Chief Medical Officer |
| Dr. H. David Humes M.D. | Co-Founder and Managing Director |
| David A. Green CPA, M.B.A. | Chief Financial Officer |
| Tom Mullen | Vice President of Operations and Product Development |
| Tim Varacek | Senior Vice President of Commercial and Business Operations |
| Sai P. Iyer | Senior Vice President of Medical Affairs and Research |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 13, 2024 | 10-Q | Quarterly Report |
| Nov 13, 2024 | 8-K | Current Report |
| Nov 4, 2024 | DEF 14A | Other definitive proxy statements |
| Oct 24, 2024 | PRE 14A | Other preliminary proxy statements |
| Oct 22, 2024 | 8-K | Current Report |
| Aug 27, 2024 | EFFECT | Notice of Effectiveness |
| Aug 27, 2024 | EFFECT | Notice of Effectiveness |
| Aug 21, 2024 | 8-K | Current Report |
| Aug 21, 2024 | 424B5 | Filing |